MedTrace Logo

Clinical Trial for Post-marketing Evaluation of Sheng Bai Oral Liquid

NCT03413358 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2018-01-29

No results posted yet for this study

Summary

The purpose of the study is to evaluate the efficacy and safety of Sheng Bai oral liquid in prevention and treatment of the decrease of neutrophilics after chemotherapy in patients with non-small-cell lung cancer.

Conditions

  • Non-small-Cell Lung Cancer

Interventions

DRUG

Sheng Bai oral liquid

Drug: Sheng Bai oral liquid 40 mL, oral use, thrice daily after screening on the same day in the second course of the chemotherapy. Subjects will be treated for 2 courses

DRUG

Platinum-based two medicine (carboplatin / cisplatin) .

Using Platinum-based two medicine (carboplatin / cisplatin)

Sponsors & Collaborators

  • Hubei Mon Yan Pharmaceutical Co., Ltd

    collaborator UNKNOWN

  • BeiJing Yijiayi Medicine Techonoloy Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Hongsheng Lin, Professor · CHINA ACADENY OF CHINESE MEDICAL SCIENCES Guang'anmen Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-15
Primary Completion
2019-10-31
Completion
2019-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03413358 on ClinicalTrials.gov